Sarepta stock downgraded at Citi on valuation (NASDAQ:SRPT)
2024-06-26
Dmitry Vinogradov Following a sharp rally last week on FDA label expansion for its muscle disorder therapy Elevidys, Sarepta Therapeutics (NASDAQ:SRPT) continued to trade lower in the premarket Wednesday as Citi downgraded the stock based on valuation. The shares of the Cambridge, Massachusetts-based biotech surged more than 30% on FridayContinue Reading